Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is Nebokitug, a humanized monoclonal antibody attenuates the basic function of CCL24 that has completed phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC); and is in phase 2 clinical trial to treat systemic sclerosis (SSc). Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel. Show more

Location: Building 7, Tel Aviv, 6158002, Israel | Website: https://www.chemomab.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

22.42M

52 Wk Range

$0.87 - $2.55

Previous Close

$1.17

Open

$1.15

Volume

97,616

Day Range

$1.13 - $1.19

Enterprise Value

427.3M

Cash

10.56M

Avg Qtr Burn

N/A

Insider Ownership

15.27%

Institutional Own.

16.98%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.